This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biogen Wins FDA Approval of MS Pill

CAMBRIDGE, Mass. ( TheStreet) -- The U.S. Food and Drug Administration approved a new multiple sclerosis pill from Biogen Idec (BIIB - Get Report) on Wednesday -- a decision widely expected by investors.

Biogen shares rose 3% to $182.83 following the FDA's announcement that it had approved the drug, which will be sold under the brand name Tecfidera.

Tecfidera is the third MS pill to be approved in the U.S. following Novartis' (NVS - Get Report) Gilenya and Sanofi's (SNY - Get Report) Aubagio, but Tecfidera sales are expected to top them all and even compete against the long-approved injectable therapies.

Analysts, on average, are forecasting Tecfidera sales to reach $3.25 billion in 2017, according to Bloomberg.

"Looking forward, based on physician feedback... and our prior survey work, we expect a solid launch of Tecfidera and our sense is that there is a bolus of patients in the queue ready to transition to therapy at high volume MS centers. However, we believe that Street expectations likely already account for this and then some," said J.P. Morgan biotech analyst Geoff Meacham, in a note to clients Wednesday afternoon.

ISI Group analyst Mark Schoenebaum says investors are expecting Biogen to price Tecfidera at $51,000 and generate $291 million in 2013 U.S. sales.

Last Friday, Tecfidera also won a recommendation for approval from European regulators.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BIIB $398.68 0.00%
NVS $103.85 0.00%
SNY $50.73 0.00%
AAPL $132.54 0.00%
FB $80.54 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs